NOX 1.52% 6.7¢ noxopharm limited

Ann: Veyonda and Opdivo IONIC Study First Patient Dosed, page-5

  1. 580 Posts.
    lightbulb Created with Sketch. 355
    Yes! This is fantastic news. I was getting worried for a second or two.

    Congratulations NOX and Prof De Souza.

    I know this is the possibly the least developed of the 4 oncology pillars, but it's one I'm perhaps most interested in, given recent research in S1P.
 
watchlist Created with Sketch. Add NOX (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.